IO Immunology—Bispecific Antibody Targets

IO Immune—Bispecific Antibody Target Proteins encompass core target molecules for immuno-oncology (IO) and bispecific antibody research and development. These include immune checkpoint and immunoregulatory molecules such as PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, 4-1BB, and CD3, which enhance T-cell antitumor activity by blocking immunosuppressive signals or bridging immune cells and tumor cells. These products are widely used in bispecific antibody structural design, binding activity validation, functional assessment, and research on combination immunotherapy regimens, serving as essential tool proteins for the development of immuno-oncology drugs.